Cara Therapeutics, Inc.
Profile
Cara Therapeutics cares about pain therapy. The clinical-stage biopharmaceutical company focuses on developing and commercializing new chemical products designed to alleviate pain by selectively targeting kappa opioid receptors. Its proprietary class of product candidates target the body's peripheral nervous system. In test with patients with moderate-to-severe pain they have have demonstrated efficacy without inducing many of the undesirable side effects often associated with pain therapeutics. Cara's most advanced product candidate, is intravenous CR845. The company filed to go public in 2014.
Cara Therapeutics is a clinical-stage biotechnology company located in Stamford, CT focused on developing and commercializing new chemical entities designed to fundamentally change the way pruritus, acute pain, and chronic pain are managed. We aim to achieve this by developing new products that selectively target the body’s peripheral kappa opioid receptors. Cara is developing a novel and proprietary class of product candidates that target the body’s peripheral nervous system and have demonstrated initial efficacy in patients with moderate-to-severe pain and pruritus (itch) without inducing many of the undesirable side effects typically associated with currently available pain and itch therapeutics.